CalciMedica Inc. (NASDAQ:CALC) Stock Rated “Hold” by Sell-Side Analysts

Shares of CalciMedica Inc. (NASDAQ:CALC) have earned an average rating of “Hold” from the five brokerages that are currently covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, two have given a hold recommendation and two have issued a buy recommendation on the company. The average 1 year price target among brokers that have issued ratings on the stock in the last year is $50.00.

A number of research analysts have weighed in on the stock. Guggenheim initiated coverage on shares of CalciMedica in a report on Thursday, August 20th. They issued a “buy” rating for the company. Wall Street Zen lowered shares of CalciMedica from a “sell” rating to a “strong sell” rating in a research report on Saturday, September 12th. UBS Group reaffirmed a “neutral” rating on shares of CalciMedica in a research note on Thursday, August 13th. HC Wainwright reaffirmed a “neutral” rating on shares of CalciMedica in a research note on Wednesday, July 29th. Finally, Weiss Ratings raised shares of CalciMedica from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, August 27th.

CalciMedica Stock Up 0.9%

Shares of CALC stock opened at $1.08 on Friday. The company has a debt-to-equity ratio of 1.67, a current ratio of 5.58 and a quick ratio of 5.58. The company has a market cap of $7.38 million, a price-to-earnings ratio of -0.16 and a beta of 0.76. The stock’s fifty day moving average price is $2.17 and its 200 day moving average price is $3.15. CalciMedica has a 1-year low of $1.03 and a 1-year high of $36.00.

CalciMedica (NASDAQ:CALC) last posted its quarterly earnings data on Tuesday, August 11th. The company reported ($0.45) EPS for the quarter, topping the consensus estimate of ($1.42) by $0.97. On average, research analysts expect that CalciMedica will post -5.25 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in CalciMedica stock. Renaissance Technologies LLC increased its holdings in CalciMedica Inc. (NASDAQ:CALC) by 45.0% in the 1st quarter, according to its most recent disclosure with the SEC. The firm owned 128,075 shares of the company’s stock after acquiring an additional 39,775 shares during the period. Renaissance Technologies LLC owned approximately 0.81% of CalciMedica worth $69,000 at the end of the most recent quarter.

CalciMedica Company Profile

CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapies for serious inflammatory and immune-mediated diseases. The company’s research centers on calcium release-activated calcium (CRAC) channels, which play a role in the activation of immune cells and the inflammatory response.

CalciMedica’s lead product candidate is zelnecirnon, formerly known as Auxora or CM4620. It is an investigational, selective CRAC channel inhibitor being studied for acute and chronic inflammatory conditions, including severe acute pancreatitis and acute kidney injury associated with severe inflammatory illness.